Warning! GuruFocus detected
1 Severe warning sign
with NKTX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Nkarta Inc
NAICS : 541714
SIC : 2834
ISIN : US65487U1088
Share Class Description:
NKTX: Ordinary SharesDescription
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.33 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.67 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12 | |||||
| 3-Year EPS without NRI Growth Rate | 15.2 | |||||
| 3-Year FCF Growth Rate | 11.6 | |||||
| 3-Year Book Growth Rate | -8.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.46 | |||||
| 9-Day RSI | 66.39 | |||||
| 14-Day RSI | 62.05 | |||||
| 3-1 Month Momentum % | -42.57 | |||||
| 6-1 Month Momentum % | -57.06 | |||||
| 12-1 Month Momentum % | -79.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.45 | |||||
| Quick Ratio | 14.45 | |||||
| Cash Ratio | 14.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28.9 | |||||
| Shareholder Yield % | -146.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -26.68 | |||||
| ROA % | -21.39 | |||||
| ROIC % | -63.29 | |||||
| 3-Year ROIIC % | -20.3 | |||||
| ROC (Joel Greenblatt) % | -110.55 | |||||
| ROCE % | -26.32 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.37 | |||||
| Price-to-Tangible-Book | 0.37 | |||||
| EV-to-EBIT | 0.29 | |||||
| EV-to-Forward-EBIT | -0.1 | |||||
| EV-to-EBITDA | 0.31 | |||||
| EV-to-FCF | 0.36 | |||||
| Price-to-Net-Current-Asset-Value | 0.83 | |||||
| Price-to-Net-Cash | 0.86 | |||||
| Earnings Yield (Greenblatt) % | 344.83 | |||||
| FCF Yield % | -69.53 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers